Tag Archives: Alan Carr

Alnylam Pharma (ALNY) Receives a Buy from Needham

Needham analyst Alan Carr maintained a Buy rating on Alnylam Pharma (NASDAQ: ALNY) today and set a price target of $152. The company’s shares opened today at $94.10. Carr commented: “Alnylam is expected to announce results of an interim analysis

Needham Maintains Their Buy Rating on Zealand Pharma A/S (ZEAL)

Needham analyst Alan Carr maintained a Buy rating on Zealand Pharma A/S (NASDAQ: ZEAL) today and set a price target of $26. The company’s shares opened today at $15.91. Carr commented: “Zealand mgmt hosted a conference call today to discuss

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) and Eagle Pharmaceuticals Inc (NASDAQ:EGRX). Biohaven Pharmaceutical Holding Co Ltd (BHVN) In a report released today, Alan Carr from

Needham Keeps a Buy Rating on Alnylam Pharma (ALNY)

In a report released today, Alan Carr from Needham maintained a Buy rating on Alnylam Pharma (NASDAQ: ALNY), with a price target of $152. The company’s shares closed on Friday at $97.38. Carr observed: “Alnylam and the FDA announced Friday

Analysts Offer Insights on Healthcare Companies: Tetraphase (NASDAQ: TTPH) and La Jolla Pharma (NASDAQ: LJPC)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tetraphase (NASDAQ:TTPH) and La Jolla Pharma (NASDAQ:LJPC). Tetraphase (TTPH) Needham analyst Alan Carr maintained a Hold rating on Tetraphase today. The company’s shares

Intercept Pharma (ICPT) Receives a Hold from Needham

Needham analyst Alan Carr maintained a Hold rating on Intercept Pharma (NASDAQ: ICPT) today. The company’s shares opened today at $100.83. Carr commented: “Intercept reported $34.5M in U.S. Ocaliva sales (+21% q/q; +24% y/y), slightly above our $34.0M and consensus